Back to Search Start Over

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Authors :
Goode, Ellen L.
Block, Matthew S.
Kalli, Kimberly R.
Vierkant, Robert A.
Chen, Wenqian
Fogarty, Zachary C.
Gentry-Maharaj, Aleksandra
Toloczko, Aleksandra
Hein, Alexander
Bouligny, Aliecia L.
Jensen, Allan
Osorio, Ana
Hartkopf, Andreas D.
Ryan, Andy
Chudecka-Glaz, Anita
Magliocco, Anthony M.
Hartmann, Arndt
Jung, Audrey Y
Gao, Bo
Hernandez, Brenda Y.
Fridley, Brooke L.
McCauley, Bryan M.
Kennedy, Catherine J.
Wang, Chen
Karpinskyj, Chloe
de Sousa, Christiani B.
Tiezzi, Daniel G.
Wachter, David L.
Herpel, Esther
Taran, Florin Andrei
Modugno, Francesmary
Nelson, Gregg
Lubinski, Jan
Menkiszak, Janusz
Alsop, Jennifer
Lester, Jenny
García-Donas, Jesús
Nation, Jill
Hung, Jillian
Palacios, José
Rothstein, Joseph H.
Kelley, Joseph L.
de Andrade, Jurandyr M.
Robles-Díaz, Luis
Intermaggio, Maria P.
Widschwendter, Martin
Beckmann, Matthias W.
Ruebner, Matthias
Jimenez-Linan, Mercedes
Singh, Naveena
Oszurek, Oleg
Harnett, Paul R.
Rambau, Peter F.
Sinn, Peter
Wagner, Philipp
Ghatage, Prafull
Sharma, Raghwa
Edwards, Robert P.
Ness, Roberta B.
Orsulic, Sandra
Brucker, Sara Y.
Johnatty, Sharon E.
Longacre, Teri A.
Eilber, Ursula
McGuire, Valerie
Sieh, Weiva
Natanzon, Yanina
Li, Zheng
Whittemore, Alice S.
deFazio, Anna
Staebler, Annette
Karlan, Beth Y.
Gilks, Blake
Bowtell, David D.
Høgdall, Estrid
Candido dos Reis, Francisco J.
Steed, Helen
Campbell, Ian G.
Gronwald, Jacek
Benítez, Javier
Koziak, Jennifer M.
Chang-Claude, Jenny
Moysich, Kirsten B.
Kelemen, Linda E.
Cook, Linda S.
Goodman, Marc T.
García, María José
Fasching, Peter A.
Kommoss, Stefan
Deen, Suha
Kjaer, Susanne K.
Menon, Usha
Brenton, James D.
Pharoah, Paul D. P.
Chenevix-Trench, Georgia
Huntsman, David G.
Winham, Stacey J.
Köbel, Martin
Ramus, Susan J.
Source :
JAMA Oncology; December 2017, Vol. 3 Issue: 12 pe173290-e173290, 1p
Publication Year :
2017

Abstract

IMPORTANCE: Cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors. OBJECTIVE: To define the prognostic role of CD8+ TILs in epithelial ovarian cancer. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years. EXPOSURES: Following immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines. MAIN OUTCOMES AND MEASURES: Overall survival time. RESULTS: The final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form. CONCLUSIONS AND RELEVANCE: This study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Details

Language :
English
ISSN :
23742437 and 23742445
Volume :
3
Issue :
12
Database :
Supplemental Index
Journal :
JAMA Oncology
Publication Type :
Periodical
Accession number :
ejs44372218
Full Text :
https://doi.org/10.1001/jamaoncol.2017.3290